17.31

0.12% 0.02

After Hours: 17.31

Amneal Pharmaceuticals Inc (AMRX)

Overview News Price History Option Chain Discussions Forecast

Amneal Pharmaceuticals Inc stock is traded at $17.31, with a volume of 2.24M. It is up +0.12% in the last 24 hours and up +31.44% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Previous Close:

$17.29

Open:

$17.3

24h Volume:

2.24M

Relative Volume:

1.25

Market Cap:

$5.52B

Revenue:

$3.05B

Net Income/Loss:

$181.32M

P/E Ratio:

46.41

EPS:

0.373

Net Cash Flow:

$186.11M

1W Performance:

+3.90%

1M Performance:

+31.44%

6M Performance:

+34.39%

1Y Performance:

+113.97%

1-Day Range:

$17.17

$17.49

1-Week Range:

$16.81

$17.86

52-Week Range:

$7.665

$17.86

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name

Amneal Pharmaceuticals Inc

Sector

Healthcare (1095)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

908-947-3120

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater

Employee

5,210

Twitter

@amnealpharma

Next Earnings Date

2026-08-04

Latest SEC Filings

AMRX's Discussions on Twitter

Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMRX Amneal Pharmaceuticals Inc	17.31	5.50B	3.05B	181.32M	186.11M	0.373
TAK Takeda Pharmaceutical Co Adr	16.03	50.27B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.33	40.72B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	33.88	38.67B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	71.86	31.90B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	541.83	23.03B	3.17B	1.29B	1.01B	27.09

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-26	Initiated	UBS	Buy
Dec-09-25	Initiated	Barclays	Overweight
Jun-06-25	Initiated	Goldman	Buy
Feb-24-25	Upgrade	JP Morgan	Neutral → Overweight
Sep-06-24	Upgrade	JP Morgan	Underweight → Neutral
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform
Mar-08-21	Upgrade	Goldman	Sell → Buy
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy
Jul-27-20	Initiated	Goldman	Sell
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy
Mar-20-19	Initiated	SunTrust	Buy
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Dec-14-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-16-18	Downgrade	SunTrust	Buy → Hold
Aug-13-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jul-23-18	Initiated	Morgan Stanley	Overweight
Jun-22-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

Jun 29, 2026

Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters

Jun 29, 2026

Amneal to Buy Kashiv for $375M Cash + 28.9M Shares (NASDAQ: AMRX) - Stock Titan

Jun 29, 2026

EMA Recommends Approval of Hopledo for Parkinson's Disease - Intellectia AI

Jun 29, 2026

Zambon and Amneal Receive Positive CHMP Opinion for Hopledo in Parkinson’s Disease in Europe - Quiver Quantitative

Jun 29, 2026

EU regulator backs Amneal’s Parkinson’s drug after Phase 3 data - Stock Titan

Jun 29, 2026

Does Amneal (AMRX) Joining Three Russell 2000 Defensive Indexes Recast Its Risk Profile? - simplywall.st

Jun 29, 2026

Jun 28, 2026

Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Value-Defensive Index - marketscreener.com

Jun 28, 2026

Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth-Defensive Index - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Form DEF 14A Amneal Pharmaceuticals Inc Class A For: 26 June - Investing.com UK

Jun 27, 2026

2DT Forecast — Price Target — Prediction for 2027 - TradingView

Jun 27, 2026

Jun 25, 2026

Amneal Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:AMRX) - TradingView

Jun 25, 2026

AMRX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Amneal Pharmaceuticals (AMRX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat

Jun 25, 2026

Jun 23, 2026

Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX) - MSN

Jun 23, 2026

Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD - Investing.com

Jun 23, 2026

Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD By Investing.com - Investing.com South Africa

Jun 23, 2026

Jun 22, 2026

Rytvela from Amneal Pharmaceuticals Inc.biosimilar for chronic uveitis care - AD HOC NEWS

Jun 22, 2026

Amgen Inc. v. Amneal Pharm. LLC United States Court of Appeals of the Federal Circuit, 2020 945 F.3d 1368, 2020 - Sage Journals

Jun 22, 2026

Jun 21, 2026

Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally - Sahm

Jun 21, 2026

Jun 18, 2026

Amneal (AMRX) agrees to buy Kashiv for $375M cash plus equity and milestones - Stock Titan

Jun 18, 2026

Jun 17, 2026